PT2968369T - Esteroides neuroativos e métodos para o seu uso - Google Patents

Esteroides neuroativos e métodos para o seu uso

Info

Publication number
PT2968369T
PT2968369T PT14774060T PT14774060T PT2968369T PT 2968369 T PT2968369 T PT 2968369T PT 14774060 T PT14774060 T PT 14774060T PT 14774060 T PT14774060 T PT 14774060T PT 2968369 T PT2968369 T PT 2968369T
Authority
PT
Portugal
Prior art keywords
methods
neuroactive steroids
neuroactive
steroids
Prior art date
Application number
PT14774060T
Other languages
English (en)
Portuguese (pt)
Inventor
Martinez Botella Gabriel
L Harrison Boyd
J Robichaud Albert
G Salituro Francesco
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of PT2968369T publication Critical patent/PT2968369T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT14774060T 2013-03-13 2014-03-13 Esteroides neuroativos e métodos para o seu uso PT2968369T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779735P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
PT2968369T true PT2968369T (pt) 2018-12-05

Family

ID=51625437

Family Applications (3)

Application Number Title Priority Date Filing Date
PT14774060T PT2968369T (pt) 2013-03-13 2014-03-13 Esteroides neuroativos e métodos para o seu uso
PT211728597T PT3932932T (pt) 2013-03-13 2014-03-13 Esteroides neuroativos e métodos para o seu uso
PT181900341T PT3461834T (pt) 2013-03-13 2014-03-13 Esteroides neuroativos

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT211728597T PT3932932T (pt) 2013-03-13 2014-03-13 Esteroides neuroativos e métodos para o seu uso
PT181900341T PT3461834T (pt) 2013-03-13 2014-03-13 Esteroides neuroativos

Country Status (25)

Country Link
US (6) US20160031930A1 (OSRAM)
EP (4) EP3932932B8 (OSRAM)
JP (6) JP6255082B2 (OSRAM)
CN (3) CN112375115A (OSRAM)
AU (5) AU2014243773B2 (OSRAM)
BR (1) BR112015022174B1 (OSRAM)
CA (2) CA2905359C (OSRAM)
CY (2) CY1120934T1 (OSRAM)
DK (3) DK2968369T3 (OSRAM)
ES (3) ES2699445T3 (OSRAM)
FI (1) FI3932932T3 (OSRAM)
HR (3) HRP20181994T1 (OSRAM)
HU (2) HUE055668T2 (OSRAM)
IL (3) IL280068B2 (OSRAM)
LT (3) LT3461834T (OSRAM)
MX (2) MX362544B (OSRAM)
PL (3) PL2968369T3 (OSRAM)
PT (3) PT2968369T (OSRAM)
RS (3) RS67266B1 (OSRAM)
RU (1) RU2684103C2 (OSRAM)
SI (3) SI3932932T1 (OSRAM)
SM (3) SMT201800657T1 (OSRAM)
TR (1) TR201817995T4 (OSRAM)
WO (1) WO2014160480A1 (OSRAM)
ZA (1) ZA201506729B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
KR101815076B1 (ko) 2010-10-27 2018-01-30 메루스 오디오 에이피에스 멀티­레벨 펄스폭 변조를 사용하는 오디오 증폭기
JP6205362B2 (ja) 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107405352A (zh) 2014-10-07 2017-11-28 萨奇治疗股份有限公司 神经活性化合物及其使用方法
SMT202100226T1 (it) * 2015-07-06 2021-05-07 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
EP3319610A4 (en) * 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
PL3436022T3 (pl) * 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055263T2 (hu) * 2016-07-07 2021-11-29 Sage Therapeutics Inc 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
ES2935057T3 (es) * 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
CN119350419A (zh) * 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
ES3038660T3 (en) 2016-10-18 2025-10-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
CN106632565A (zh) * 2016-11-07 2017-05-10 湖南科瑞生物制药股份有限公司 一种合成胆固醇的新方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
BR112023023082A2 (pt) * 2021-05-04 2024-01-30 Sage Therapeutics Inc Esteroide neuroativo para o tratamento de comprometimento cognitivo suave associado a doença de parkinson
JP2024520805A (ja) 2021-06-11 2024-05-24 セージ セラピューティクス， インコーポレイテッド アルツハイマー病の治療のための神経活性ステロイド
US20240368214A1 (en) * 2021-08-25 2024-11-07 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
WO2023049295A1 (en) * 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
KR20240134889A (ko) * 2021-12-13 2024-09-10 세이지 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 신경활성 스테로이드
CN114478672B (zh) * 2022-01-27 2024-06-14 浙江仙居君业药业有限公司 一种he3286的合成方法
AU2023287695A1 (en) 2022-06-24 2025-02-06 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
WO2024015201A1 (en) 2022-07-12 2024-01-18 Sage Therapeutics, Inc. Crystalline form of a neuroactive steroid
WO2024229290A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of use thereof
WO2025227053A1 (en) * 2024-04-25 2025-10-30 Sage Therapeutics, Inc. Nmda receptor positive allosteric modulatory compositions and methods of use thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (OSRAM) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0752860B1 (en) * 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstanes and pregnanes for allosteric modulation of gaba receptor
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
CA2205919A1 (en) 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
RU2182909C2 (ru) 1995-06-23 2002-05-27 Ново Нордиск А/С Стероиды, способ регулирования мейоза
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
CA2331299A1 (en) 1998-05-11 1999-11-18 Novo Nordisk A/S Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
AU3701199A (en) 1998-05-13 1999-11-29 Novo Nordisk A/S Meiosis regulating compounds
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
EP1392713B1 (en) * 2001-05-03 2007-10-17 The University of Chicago Liver x receptor agonists
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
AU2002360489A1 (en) 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
CN102727501A (zh) 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
PL213697B1 (pl) 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
WO2004055201A2 (en) 2002-12-13 2004-07-01 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
KR101358078B1 (ko) * 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) * 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
US8273747B2 (en) 2006-11-02 2012-09-25 Curis, Inc. Small organic molecule regulators of cell proliferation
PL2711371T3 (pl) 2006-11-21 2018-06-29 Asarina Pharma Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
US20110118353A1 (en) 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
JP2011505357A (ja) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en) 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X-RECEPTOR AGONISTS
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20120136378A (ko) * 2010-03-03 2012-12-18 사토리 파마슈티컬즈, 인코포레이티드 신경변성 질환을 치료하는데 유용한 화합물
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
WO2012142039A1 (en) 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
EP2736919A4 (en) 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
JP6205362B2 (ja) 2011-09-08 2017-09-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性のステロイド、組成物、およびそれらの使用
WO2013054822A1 (en) 2011-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
WO2014028942A2 (en) 2012-08-17 2014-02-20 Trueex Group Llc Interoffice bank offered rate financial product and implementation
RS57390B1 (sr) 2012-12-18 2018-09-28 Univ Washington Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja
JP2016505038A (ja) 2013-01-23 2016-02-18 スファエラ ファーマ プライベート リミテッド ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物
EA031905B1 (ru) 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
SMT201800657T1 (it) * 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
AU2014243819A1 (en) 2013-03-13 2015-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
EP3102230B1 (en) 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107405352A (zh) 2014-10-07 2017-11-28 萨奇治疗股份有限公司 神经活性化合物及其使用方法
EP3319610A4 (en) 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
SG10202002655VA (en) 2015-07-06 2020-05-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
SMT202100226T1 (it) 2015-07-06 2021-05-07 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
PL3436022T3 (pl) 2016-04-01 2022-08-08 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE055263T2 (hu) 2016-07-07 2021-11-29 Sage Therapeutics Inc 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
CN119350419A (zh) 2016-10-18 2025-01-24 萨奇治疗股份有限公司 氧甾醇及其使用方法
ES3038660T3 (en) 2016-10-18 2025-10-14 Sage Therapeutics Inc Oxysterols and methods of use thereof
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
CN110945006A (zh) 2017-06-23 2020-03-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
SG10202110563YA (en) 2017-11-10 2021-11-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
MX362544B (es) 2019-01-24
JP7715692B2 (ja) 2025-07-30
CA2905359C (en) 2021-05-25
AU2025203021A1 (en) 2025-05-22
JP6255082B2 (ja) 2017-12-27
ES3042115T3 (en) 2025-11-18
IL280068A (en) 2021-03-01
US20220064207A1 (en) 2022-03-03
US11104701B2 (en) 2021-08-31
IL318314A (en) 2025-03-01
IL280068B2 (en) 2025-06-01
IL241301B (en) 2021-01-31
EP3461834B1 (en) 2021-05-19
AU2022279366B2 (en) 2025-02-06
AU2014243773A1 (en) 2015-10-01
PL3932932T3 (pl) 2025-11-24
MX388210B (es) 2025-03-19
AU2014243773B2 (en) 2018-12-13
JP7317898B2 (ja) 2023-07-31
JP6530804B2 (ja) 2019-06-12
CY1120934T1 (el) 2019-12-11
US20160031930A1 (en) 2016-02-04
BR112015022174A8 (pt) 2019-11-26
WO2014160480A1 (en) 2014-10-02
SMT202500336T1 (it) 2025-11-10
PT3932932T (pt) 2025-09-29
HK1220375A1 (en) 2017-05-05
LT3932932T (lt) 2025-09-10
EP4643945A8 (en) 2025-12-17
BR112015022174B1 (pt) 2022-07-05
US10227375B2 (en) 2019-03-12
US20190127414A1 (en) 2019-05-02
EP2968369A4 (en) 2016-09-14
SI2968369T1 (sl) 2019-01-31
SI3461834T1 (sl) 2021-11-30
CN105246486B (zh) 2020-11-03
RU2015143466A (ru) 2017-04-18
ES2699445T3 (es) 2019-02-11
HRP20211300T1 (hr) 2021-11-12
CY1124629T1 (el) 2022-07-22
JP2021152086A (ja) 2021-09-30
AU2021200205B2 (en) 2022-09-01
DK2968369T3 (en) 2018-12-17
SMT202100475T1 (it) 2021-09-14
EP3932932A1 (en) 2022-01-05
CN112375115A (zh) 2021-02-19
EP3932932B8 (en) 2025-11-19
EP4643945A2 (en) 2025-11-05
RS67266B1 (sr) 2025-10-31
MX2015012430A (es) 2016-02-03
AU2019201275B2 (en) 2020-10-15
ZA201506729B (en) 2017-09-27
US20240287125A1 (en) 2024-08-29
WO2014160480A8 (en) 2015-01-08
JP2025120299A (ja) 2025-08-15
PL3461834T3 (pl) 2021-12-27
AU2019201275A1 (en) 2019-03-14
AU2022279366A1 (en) 2023-01-19
PT3461834T (pt) 2021-09-10
EP2968369A1 (en) 2016-01-20
NZ751196A (en) 2020-10-30
HUE055668T2 (hu) 2021-12-28
DK3461834T3 (da) 2021-08-23
AU2021200205A1 (en) 2021-03-18
CN118702755A (zh) 2024-09-27
RS62235B1 (sr) 2021-09-30
US20170305960A1 (en) 2017-10-26
CA2905359A1 (en) 2014-10-02
TR201817995T4 (en) 2019-02-21
RU2019109033A (ru) 2019-05-21
JP2016513663A (ja) 2016-05-16
JP2018030890A (ja) 2018-03-01
US20180237470A1 (en) 2018-08-23
RU2684103C2 (ru) 2019-04-04
CA3114062A1 (en) 2014-10-02
SMT201800657T1 (it) 2019-01-11
HUE072324T2 (hu) 2025-11-28
JP2019135261A (ja) 2019-08-15
EP3461834A1 (en) 2019-04-03
EP2968369B1 (en) 2018-08-29
HRP20251221T1 (hr) 2025-12-05
CN105246486A (zh) 2016-01-13
EP3932932B1 (en) 2025-07-16
RS58166B1 (sr) 2019-03-29
FI3932932T3 (fi) 2025-10-15
NZ712141A (en) 2020-10-30
PL2968369T3 (pl) 2019-03-29
IL241301A0 (en) 2015-11-30
LT3461834T (lt) 2021-10-25
LT2968369T (lt) 2018-12-27
HRP20181994T1 (hr) 2019-03-08
BR112015022174A2 (pt) 2017-07-18
ES2886506T3 (es) 2021-12-20
IL280068B1 (en) 2025-02-01
SI3932932T1 (sl) 2025-10-30
DK3932932T3 (da) 2025-08-18
JP2022180606A (ja) 2022-12-06
US11905309B2 (en) 2024-02-20

Similar Documents

Publication Publication Date Title
PT2968369T (pt) Esteroides neuroativos e métodos para o seu uso
IL286970A (en) Neuroactive steroids and methods of use thereof
BR112016000975A2 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
PT2943078T (pt) Métodos e composições para consumíveis
CL2015003440A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso
DK2986624T3 (da) Neuroaktive 19-nor-steroider til terapeutisk anvendelse
EP2972772A4 (en) ON-SITE SNAPSHOTS
BR112016003480A2 (pt) ensaios para detecção de molécula única e seu uso
BR112015028171A2 (pt) inibidores de acc e seu uso
BR302014001267S1 (pt) Configuração aplicada em liquidificador
BR112015021732A2 (pt) dispositivo para uso terapêutico
BR302014001632S1 (pt) Configuração aplicada em filtro para liquidificador
FI20165295A7 (fi) Kiinnitin purettavalle rakenteelle
BR112015029267A2 (pt) processos para a preparação de desidroepiandrosterona e seus intermediários
PT2951866T (pt) Dispositivo optoeletrónico e método para produzir o mesmo
BR112017026909A2 (pt) soluções de esteróides neuroativos e seus métodos de uso
DE112014000391A5 (de) Lärmarmes und hocheffizientes Flugzeug
BR112016004943A2 (pt) aparelho médico e uso
GB201315576D0 (en) Improved checkpoint and restart
BR112016012395A2 (pt) dispositivo para moagem
PT2946448T (pt) Estrutura para armário
DE112014002295A5 (de) Zerkleinerungsvorrichtung
FR3014823B1 (fr) Remorque abaissable et escamotable
ES1093332Y (es) Premarco para puertas y ventanas
BR302013004537S1 (pt) Configuração aplicada em abrigo móvel para construções